MCID: BLD039
MIFTS: 40

Bladder Adenocarcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Adenocarcinoma

MalaCards integrated aliases for Bladder Adenocarcinoma:

Name: Bladder Adenocarcinoma 12 15 17 74
Bladder Adenocarcinoma, Not Otherwise Specified 12
Adenocarcinoma of the Urinary Bladder 12
Adenocarcinoma of Bladder 12
Adenocarcinoma Bladder 56

Classifications:



External Ids:

Disease Ontology 12 DOID:3711
NCIt 51 C39836 C4032
UMLS 74 C0279682

Summaries for Bladder Adenocarcinoma

Disease Ontology : 12 A bladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Bladder Adenocarcinoma, also known as bladder adenocarcinoma, not otherwise specified, is related to clear cell adenocarcinoma and mammary paget's disease, and has symptoms including dysuria An important gene associated with Bladder Adenocarcinoma is UCA1 (Urothelial Cancer Associated 1), and among its related pathways/superpathways are Cytoskeleton remodeling Regulation of actin cytoskeleton by Rho GTPases and Pathways Affected in Adenoid Cystic Carcinoma. The drugs Epirubicin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lung, colon and liver, and related phenotype is neoplasm.

Related Diseases for Bladder Adenocarcinoma

Diseases related to Bladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 168)
# Related Disease Score Top Affiliating Genes
1 clear cell adenocarcinoma 30.2 KRT20 KRT7
2 mammary paget's disease 29.7 KRT20 KRT7
3 mucinous adenocarcinoma 29.5 CDX2 KRT20 KRT7
4 appendix adenocarcinoma 29.4 CDX2 KRT20 KRT7
5 signet ring cell adenocarcinoma 29.3 CDX2 KRT20 KRT7
6 transitional cell carcinoma 29.2 HRAS KRT20 KRT7
7 glandular cystitis 29.1 CDX2 KRT20 KRT7 UCA1
8 endometrial cancer 29.1 CTNNB1 HRAS KRT7 UCA1
9 adenocarcinoma in situ 29.0 CDX2 KRT20 KRT7
10 gastric adenocarcinoma 28.6 CDX2 CTNNB1 HRAS KRT20 KRT7
11 colorectal adenocarcinoma 28.3 CDX2 CTNNB1 HRAS KRT20 KRT7
12 lung cancer susceptibility 3 28.3 CDX2 CTNNB1 HRAS KRT20 KRT7
13 bladder signet ring cell adenocarcinoma 11.5
14 pelvic lipomatosis 11.2
15 bladder clear cell adenocarcinoma 11.2
16 bladder colloid adenocarcinoma 11.1
17 bladder colonic type adenocarcinoma 11.1
18 bladder urachal adenocarcinoma 11.1
19 bladder tubulo-cystic clear cell adenocarcinoma 11.1
20 bladder papillary clear cell adenocarcinoma 11.1
21 bladder hepatoid adenocarcinoma 11.1
22 adenocarcinoma 10.6
23 gallbladder adenoma 10.3 CTNNB1 HRAS
24 goblet cell carcinoid 10.2 CTNNB1 KRT20
25 hepatoid adenocarcinoma 10.2
26 skin squamous cell carcinoma 10.1 FBXW7 HRAS
27 serous cystadenocarcinoma 10.1 FBXW7 HRAS
28 vaginal benign neoplasm 10.1 CDX2 KRT20
29 vaginal adenoma 10.1 CDX2 KRT20
30 vaginal tubulovillous adenoma 10.1 CDX2 KRT20
31 villous adenoma 10.1 CDX2 KRT20
32 colorectal adenoma 10.1 CTNNB1 HRAS
33 skin benign neoplasm 10.1 HRAS KRT20
34 cystitis 10.0
35 urachal adenocarcinoma 10.0
36 papillary craniopharyngioma 10.0 CTNNB1 KRT7
37 craniopharyngioma 10.0 CTNNB1 KRT7
38 uterine carcinosarcoma 10.0 CTNNB1 FBXW7 HRAS
39 adenomyoma 10.0 CTNNB1 KRT7
40 female reproductive endometrioid cancer 10.0 CTNNB1 KRT7
41 pulmonary sclerosing hemangioma 10.0 CTNNB1 KRT7
42 sclerosing hemangioma 10.0 CTNNB1 KRT7
43 tubular adenocarcinoma 10.0 CDX2 KRT20
44 ovarian serous cystadenocarcinoma 10.0 FBXW7 HRAS
45 acinar cell carcinoma 10.0 CTNNB1 KRT7
46 cystadenoma 10.0 KRT20 KRT7
47 cystic basal cell carcinoma 10.0 KRT20 KRT7
48 prostate squamous cell carcinoma 10.0 HRAS KRT7
49 seminal vesicle adenocarcinoma 10.0 KRT20 KRT7
50 transverse colon cancer 10.0 KRT20 KRT7

Graphical network of the top 20 diseases related to Bladder Adenocarcinoma:



Diseases related to Bladder Adenocarcinoma

Symptoms & Phenotypes for Bladder Adenocarcinoma

UMLS symptoms related to Bladder Adenocarcinoma:


dysuria

MGI Mouse Phenotypes related to Bladder Adenocarcinoma:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 8.92 CDX2 CTNNB1 FBXW7 HRAS

Drugs & Therapeutics for Bladder Adenocarcinoma

Drugs for Bladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3 56420-45-2 41867
2
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
3
BCG vaccine Investigational Phase 3
4 Anti-Infective Agents Phase 3,Phase 2,Phase 1
5 Interferon-alpha Phase 3
6 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
7 Adjuvants, Immunologic Phase 3
8 Immunologic Factors Phase 3,Phase 2,Phase 1
9 Alkylating Agents Phase 3,Phase 2
10 Antiviral Agents Phase 3,Phase 2
11 Vaccines Phase 3,Phase 1
12 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
13 Antibiotics, Antitubercular Phase 3,Phase 2
14 interferons Phase 3
15 Topoisomerase Inhibitors Phase 3,Phase 2
16 Mitomycins Phase 3
17 Pharmaceutical Solutions Phase 3
18 Antimetabolites Phase 3,Phase 2
19 Immunosuppressive Agents Phase 3,Phase 2
20 Antimetabolites, Antineoplastic Phase 3,Phase 2
21
leucovorin Approved Phase 2 58-05-9 143 6006
22
Ifosfamide Approved Phase 2 3778-73-2 3690
23
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
24
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
25
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
26
Durvalumab Approved, Investigational Phase 2 1428935-60-7
27
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
28
Daunorubicin Approved Phase 2 20830-81-3 30323
29
Vinblastine Approved Phase 2 865-21-4 241903 13342
30
Gemcitabine Approved Phase 2 95058-81-4 60750
31
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
32
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
33
nivolumab Approved Phase 2,Phase 1 946414-94-4
34
Ipilimumab Approved Phase 2,Phase 1 477202-00-9
35
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
38 Piritrexim Investigational Phase 2 72732-56-0
39
Camptothecin Experimental Phase 2 7689-03-4
40
Rubitecan Investigational Phase 2 91421-42-0
41
Tremelimumab Investigational Phase 2 745013-59-6
42
Doxil Approved June 1999 Phase 2 31703
43 Vitamin B Complex Phase 2
44 Folate Phase 2
45 Folic Acid Antagonists Phase 2
46 Vitamin B9 Phase 2
47 topoisomerase I inhibitors Phase 2
48 Antimitotic Agents Phase 2
49
Isophosphamide mustard Phase 2 0
50 Albumin-Bound Paclitaxel Phase 2

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
3 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
4 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
5 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
6 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
7 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
8 Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Recruiting NCT03430895 Phase 2 durvalumab and tremelimumab
9 Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer Recruiting NCT03912818 Phase 2 Carboplatin;Cisplatin;Doxorubicin;Gemcitabine;Methotrexate;Vinblastine
10 Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors Recruiting NCT03866382 Phase 2 Cabozantinib;Cabozantinib S-malate
11 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
12 Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant Active, not recruiting NCT00082706 Phase 2 5-Fluorouracil (5-FU);Leucovorin;Cisplatin;Gemcitabine
13 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2 sorafenib tosylate
14 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
15 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder Unknown status NCT01124682 Phase 1
16 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
17 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
18 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib;Cabozantinib S-malate
19 Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Terminated NCT00072137 Phase 1

Search NIH Clinical Center for Bladder Adenocarcinoma

Genetic Tests for Bladder Adenocarcinoma

Anatomical Context for Bladder Adenocarcinoma

MalaCards organs/tissues related to Bladder Adenocarcinoma:

42
Lung, Colon, Liver, Ovary, Appendix, Kidney, Thymus

Publications for Bladder Adenocarcinoma

Articles related to Bladder Adenocarcinoma:

(show all 37)
# Title Authors Year
1
Incidental Gall Bladder Adenocarcinoma in Cholecystectomy Specimens; A Single Center Experience and Review of the Literature. ( 31049173 )
2018
2
Treating bladder adenocarcinoma. ( 30687599 )
2018
3
Primary bladder adenocarcinoma: Case report with long-term follow-up. ( 29785373 )
2018
4
Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. ( 27048257 )
2018
5
Bladder Adenocarcinoma: A Persisting Diagnostic Dilemma. ( 28511402 )
2017
6
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma. ( 28548125 )
2017
7
A novel treatment approach prolonging survival in an uncommon metastatic primary bladder adenocarcinoma. ( 26955660 )
2016
8
Urinary Bladder Adenocarcinoma Metastatic to the Abdominal Wall: Report of a Case with Cytohistologic Correlation. ( 27006847 )
2016
9
Anterior pelvic exenteration for exstrophic bladder adenocarcinoma: Case report and review. ( 27288750 )
2016
10
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis. ( 27427223 )
2016
11
Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen. ( 24281125 )
2015
12
Gall bladder Adenocarcinoma in a Young Girl. ( 26139973 )
2015
13
Mucinous Bladder Adenocarcinoma: Case Report and Literature Review. ( 26421206 )
2015
14
Bladder metastasis from lung adenocarcinoma: a difficult differential diagnosis with primary bladder adenocarcinoma. ( 24716732 )
2014
15
Hepatobiliary and pancreatic: coexisting cancers: Hepatic neuroendocrine carcinomas with gall bladder adenocarcinoma. ( 25040620 )
2014
16
Co-occurrence of acanthosis nigricans and bladder adenocarcinoma - case report. ( 24596525 )
2013
17
[Bladder adenocarcinoma 41 years after augmentation enterocystoplasty for tuberculosis]. ( 23589601 )
2013
18
Sweet's syndrome as the presenting manifestation of gall bladder adenocarcinoma. ( 23076693 )
2012
19
Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. ( 23121893 )
2012
20
Decoy cells and malignant cells coexisting in the urine from a transplant recipient with BK virus nephropathy and bladder adenocarcinoma. ( 22081531 )
2011
21
Coexisting metastatic choriocarcinoma and bladder adenocarcinoma of common germ cell origin. ( 22294067 )
2011
22
Bladder adenocarcinoma following gastrocystoplasty. ( 20392671 )
2010
23
Association of bladder adenocarcinoma and BK virus infection in a pancreatico-renal transplant recipient. ( 28657060 )
2010
24
In vivo reflectance confocal microscopy for cutaneous metastasis of bladder adenocarcinoma. ( 19221283 )
2009
25
Giant T4 rectal carcinoma mimicking urinary bladder adenocarcinoma accurately diagnosed by immunohistochemistry and successfully treated with total pelvic exenteration: report of a case. ( 18307003 )
2008
26
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer. ( 18604226 )
2008
27
Urinary bladder adenocarcinoma arising in a spina bifida patient. ( 18022132 )
2007
28
Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study. ( 15822823 )
2005
29
Spontaneous resolution of bladder adenocarcinoma. ( 15160537 )
2003
30
Hepatocellular carcinoma and gall bladder adenocarcinoma: two primaries with no significant risk factors. ( 19861819 )
2003
31
The prognostic importance of the nucleolar organizer region (AgNOR), Ki-67 and proliferating cell nuclear antigen (PCNA) in primary nonurachal bladder adenocarcinoma. ( 11506474 )
2001
32
Bladder adenocarcinoma: 31 reported cases. ( 11718635 )
2001
33
Recurrent bladder adenocarcinoma in an ileal conduit stoma: a case report. ( 10510893 )
1999
34
Urine cytology of primary and secondary urinary bladder adenocarcinoma. ( 9915134 )
1998
35
Bladder adenocarcinoma during pregnancy: a case report. ( 8855078 )
1996
36
Adenocarcinoma in an ileal conduit: recurrence of bladder adenocarcinoma. ( 8389497 )
1993
37
Alpha-1-antitrypsin (AAT) deposits in gall bladder adenocarcinoma and liver in partial AAT deficiency (Pi SZ phenotype). ( 6983292 )
1982

Variations for Bladder Adenocarcinoma

Expression for Bladder Adenocarcinoma

Search GEO for disease gene expression data for Bladder Adenocarcinoma.

Pathways for Bladder Adenocarcinoma

GO Terms for Bladder Adenocarcinoma

Biological processes related to Bladder Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vasculogenesis GO:0001570 9.16 CTNNB1 FBXW7
2 negative regulation of gene expression GO:0010629 9.13 CTNNB1 FBXW7 HRAS
3 vasculature development GO:0001944 8.62 CTNNB1 FBXW7

Sources for Bladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....